aflibercept
11.06.19
Biogen Gains Commercialization Rights to Anti-VEGF Biosimilar Candidates After Deal with Samsung BioepisSource: Samsung Bioepis
02.11.19
One-Year Results from Phase 3 Eylea Trial in Diabetic Retinopathy PresentedSource: Regeneron Pharmaceuticals
10.25.18
Eylea Meets Main Goals in Phase 3 Non-Proliferative Diabetic Retinopathy StudySource: Regeneron Pharmaceuticals
09.25.18
Novartis: New Analysis of Phase 3 Brolucizumab Data Reinforces Superior Reduction of Retinal FluidSource: Novartis